Hyperhidrosis Tied to Prevalence of Anxiety, Depression

Share this content:
Hyperhidrosis Tied to Prevalence of Anxiety, Depression
Hyperhidrosis Tied to Prevalence of Anxiety, Depression

FRIDAY, Nov. 18, 2016 (HealthDay News) -- Hyperhidrosis (HH) is associated with increased prevalence of anxiety and depression, in a HH severity-dependent manner, according to a study published in the December issue of the Journal of the American Academy of Dermatology.

Rayeheh Bahar, M.D., from the University of British Columbia in Vancouver, Canada, and colleagues examined the prevalence of anxiety and depression in patients with or without HH. A total of 2,017 consecutive dermatology outpatients were assessed for depression and anxiety using Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 scales.

The researchers found that the prevalence of anxiety was 21.3 percent and depression 27.2 percent in patients with HH, compared with 7.5 and 9.7 percent, respectively, in patients without HH (both P < 0.001). Positive correlations were seen for HH severity and anxiety and depression prevalence. The HH-associated increase in the prevalence of anxiety and depression was independent of demographic factors and presenting skin conditions, in multivariate analysis.

"Both single variant and multivariable analyses showed a significant association between HH and the prevalence of anxiety and depression in a HH severity-dependent manner," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »